Physician profile
Jonathan Lichtenstein
NPI 1598148900
$386.77
in general payments reported to CMS, 2019-2025
11 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.67 · 2022: $20.36 · 2024: $214 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $113.61 | 2024-2025 | Airsupra, Flumist Quadrivalent |
| Pfizer INC. | $56.36 | 2024-2025 | |
| Abbvie INC. | $37.32 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $37.11 | 2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $35.94 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $28.83 | 2024-2025 | Rexulti |
| Dexcom, INC. | $17.96 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $16.61 | 2025 | Zepbound, Mounjaro |
| Noven Therapeutics, LLC | $14.94 | 2024 | Secuado, Xelstrym |
| Genentech USA, INC. | $14.05 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lichtenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.